You are here

New Drug Application for First Digital Medicine Under Review

Companies pursue regulatory filing for drug/device combo

The FDA accepted a drug/device product application combining aripiprazole (Abilify, Otsuka) with Proteus’ ingestible sensor in a single tablet, which will record ingestion and, with the patient’s consent, share the information with caregivers and health care professionals. The application marks the first time an FDA-approved medication has been submitted with a sensor within the drug dosage to measure adherence and response.

The tablet contains an ingestible sensor that communicates with a wearable sensor patch and a medical software app to measure adherence to treatment in adults with schizophrenia and in those with manic and mixed episodes associated with bipolar I disorder, and to measure  adjunctive therapy for major depressive disorder.

When aripiprazole with the embedded ingestible sensor is ingested, the sensor sends a signal to the wearable Proteus patch after it reaches the stomach. The patch records and time-stamps the information from the sensor in addition to collecting other patient metrics, including rest, body angle, and activity patterns. This information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and (only with their consent) to their physicians and/or caregivers. Patients view the information using a secure local software application on their mobile phone or device. Physicians and caregivers view the data using secure web portals.

Source: Otsuka, September 11, 2015

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug